B+
Bull case
30%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
ETON
EtonFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that Eton is proving its rare-disease commercial model can compound: Q1 showed 73% product-sales growth, positive adjusted EBITDA, positive operating cash flow, and a higher revenue outlook, while DESMODA and HEMANGEOL add fresh commercial legs. If second-half launch traction and July/2H26 development milestones land, the market can support a higher multiple on a more diversified revenue base.
Posture
Defensive
Lead driver
Value
What changed
6 setup hits (3d) with net bullish as of 2026-09-08.
What can break
Adjusted gross margin fell to 67% in Q1 2026 from 69% a year earlier, with the company citing margin-dilutive INCRELEX ex-U.S. sales and prior-year licensing mix; that limits how much of the revenue beat drops through. [#SEC-8K-2026-05-14]
Momentum
98
Value
57
Sentiment
5
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $31.00 · Bull $37.00 · Bear $24.00Analysis 2026-06-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $71.00
Why
Momentum98 · Δ7d -0.1
Value57 · Δ7d -0.0
Sentiment5 · Δ7d +3.5
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 6 setup hits (3d) with net bullish as of 2026-09-08.
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Adjusted gross margin fell to 67% in Q1 2026 from 69% a year earlier, with the company citing margin-dilutive INCRELEX ex-U.S. sales and prior-year licensing mix; that limits how much of the revenue beat drops through. [#SEC-8K-2026-05-14]
- • G&A rose partly because Eton no longer qualifies for the FDA orphan program fee exemption, creating a structural expense headwind even as revenue grows. [#SEC-8K-2026-05-14] [#10-Q-2026-05-14]
- • The bear case is that much of the near-term good news is already reflected after the guidance raise, while several risks remain execution-heavy: adjusted gross margin dipped because of mix, G&A rose with lost orphan-fee exemption and headcount, debt amortization begins in May 2026, and second-half milestones are still early-stage enough that slippage or softer uptake could compress sentiment quickly.
Catalyst clock
2026-05-14
Q1 2026 print reset the near-term operating base higher
Lead driver: Value · See fundamentals
Momentum
98
9% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.0
Value
57
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.5
Sentiment
5
62% active weight
Current posture
7d trendImproving
Δ7d
+3.5
Δ21d
+4.8
Why this grade
Composite grade F. Momentum 98.4 / Value 56.6 / Sentiment 5.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-11. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-06-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.76B
Beta
1.20
Shares Out
28.58M
P/E (TTM) · Derived
-361.0
P/S (TTM)
6.38
P/FCF (TTM)
34.80
Rev YoY
+98.6%
EPS YoY
-467.4%
Gross Margin
+57.9%
Op Margin
+15.6%
Net Debt
$5.14M
Current Ratio
1.52
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data